Sugi Predict

Sugi Predict / Compounds / SCHEMBL371780

SCHEMBL371780

SCHEMBL371780

CCN(CC)CCCOc1cc2nccc(Oc3ccc(N(C(=O)[C@@]4(C(N)=O)[C@H](C)[C@@H]4C)c4ccc(F)cc4)cc3F)c2cc1OC

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MET P08581 15/20 0.52
▸ AXL P30530 8/20 0.46
▸ KDR P35968 3/20 0.46
▸ HDAC2 Q92769 2/20 0.46
▸ HDAC8 Q9BY41 2/20 0.46
▸ HDAC6 Q9UBN7 2/20 0.46
▸ RET P07949 2/20 0.46
▸ PDGFRB P09619 2/20 0.46
▸ KIT P10721 2/20 0.46
▸ FLT3 P36888 2/20 0.46
▸ HDAC10 Q969S8 1/20 0.45
▸ HDAC11 Q96DB2 1/20 0.45
▸ PLK4 O00444 1/20 0.44
▸ STK25 O00506 1/20 0.44
▸ CIT O14578 1/20 0.44
▸ AURKA O14965 1/20 0.44
▸ CHUK O15111 1/20 0.44
▸ MUSK O15146 1/20 0.44
▸ EPHB6 O15197 1/20 0.44
▸ MAPK13 O15264 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4413352 1.00 MET (0.52) METAXLKDRHDAC2HDAC8
SCHEMBL372218 1.00 MET (0.52) METAXLKDRHDAC2HDAC8
SCHEMBL371829 0.96 MET (0.51) METAXLKDRHDAC2HDAC8
SCHEMBL1483180 0.96 MET (0.51) METAXLKDRHDAC2HDAC8
SCHEMBL372054 0.96 MET (0.51) METAXLKDRHDAC2HDAC8
SCHEMBL15520481 0.96 MET (0.51) METAXLKDRHDAC2HDAC8
SCHEMBL372228 0.90 MET (0.52) METAXLKDRHDAC2HDAC8
SCHEMBL372555 0.90 MET (0.52) METAXLKDRHDAC2HDAC8
SCHEMBL371798 0.90 MET (0.49) METKDREGFRFLT1FLT4
SCHEMBL372084 0.90 MET (0.53) METAXLKDRHDAC2HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3329918-B1 C-MET MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2022-05-25 — — EP claimed
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE EXELIXIS, INC. 2021-08-19 — — US claimed
US-20200331860-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2020-10-22 — — US claimed
EP-2101759-B1 METHODS OF USING MEK INHIBITORS EXELIXIS INC (US) 2018-10-10 — — EP claimed
US-20170355678-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2017-12-14 — — US claimed
EP-2409704-B1 c-Met modulators and methods of use EXELIXIS INC (US) 2017-09-20 — — EP claimed
US-20150376133-A1 C-Met Modulators and Methods of Use EXELIXIS, INC. 2015-12-31 — — US claimed
US-20120184523-A1 C-Met Modulators and Method of Use EXELIXIS, INC. (US) 2012-07-19 — — US claimed
EP-2409704-A2 c-Met modulators and methods of use Exelixis Inc. (US) 2012-01-25 — — EP claimed
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-09-27 — — US claimed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US claimed
EP-3329918-B1 C-MET MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2022-05-25 — — EP disclosed
US-11124482-B2 C-met modulators and methods of use EXELIXIS, INC. (US) 2021-09-21 — — US disclosed
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE EXELIXIS, INC. 2021-08-19 — — US disclosed
US-20200331860-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2020-10-22 — — US disclosed
US-20090105299-A1 c-MET MODULATORS AND METHODS OF USE EXELIXIS, INC (US) 2009-04-23 — — US disclosed
US-20080166359-A1 Methods of using MEK inhibitors EXELIXIS, INC. 2008-07-10 — — US disclosed
US-20070244116-A1 c-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-10-18 — — US disclosed
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-09-27 — — US disclosed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200331860-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET MET 3/4885AXL 109/4885KDR 4/4885
US-20070054928-A1 c-Met modulators and methods of use FLT4, FLT1, MET MET 3/4885AXL 109/4885KDR 4/4885
US-20150376133-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET MET 3/4885AXL 109/4885KDR 4/4885
US-20170355678-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET MET 3/4885AXL 109/4885KDR 4/4885
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE FLT4, FLT1, MET MET 3/4885AXL 109/4885KDR 4/4885
US-20080166359-A1 Methods of using MEK inhibitors BRAF, NRAS, KRAS MET 312/4885AXL 769/4885KDR 1023/4885
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE FLT4, MET, FLT1 MET 2/4885AXL 241/4885KDR 5/4885
US-20070244116-A1 c-MET MODULATORS AND METHOD OF USE FLT4, MET, FLT1 MET 2/4885AXL 241/4885KDR 5/4885
US-11124482-B2 C-met modulators and methods of use FLT4, FLT1, MET MET 3/4885AXL 109/4885KDR 4/4885
US-20090105299-A1 c-MET MODULATORS AND METHODS OF USE FLT4, MET, FLT1 MET 2/4885AXL 239/4885KDR 5/4885
US-20120184523-A1 C-Met Modulators and Method of Use FLT4, MET, FLT1 MET 2/4885AXL 241/4885KDR 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.